摘要:
The present invention relates to a process for making 2,4-differentiated 5-trifluoromethyl pyrimidines and 2-amino-5-trifluoromethyl-pyrimidine derivatives, which compounds are useful in the preparation of pharmacologically active compounds.
摘要:
The present invention relates to a process for preparing betamimetics of formula 1, wherein n denotes 1 or 2; R1 denotes hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl; R2 denotes hydrogen, halogen, C1-4-alkyl or O—C1-4-alkyl; R3 denotes hydrogen, C1-4-alkyl, OH, halogen, O—C1-4-alkyl, O—C1-4-alkylene-COOH, O—C1-4-alkylene-COO—C1-4-alkyl.
摘要:
The present invention relates to compounds of formula I wherein RS denotes F or CF3, Ra denotes H or C1-4-alkyl and Z denotes a leaving group or an optionally substituted or protected hydroxyl group, suitable as intermediates in the synthesis of indanyloxydihydrobenzofuranylacetic acids, which are GPR40 agonists, to a process for preparing these intermediates and to the process for preparing the GPR40 agonists making use of an asymmetric catalytic hydrogenation reaction in the presence of a transition metal catalyst and a chiral auxiliary.
摘要:
The present invention relates to a compound of formula (I), wherein x Q denotes x H2O x HCl; or x 0.5 HCl x 1.5 H2O, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, processes for the stereoselective preparation of this compound, particularly for the inhalation of suitable pharmaceutical formulations and their use for the treatment of diseases, particularly tumour diseases, benign prostatic hyperplasia and diseases of the lungs and airways.
摘要翻译:本发明涉及式(I)化合物,其中x Q表示xH 2 O·HCl; 或x 0.5 HCl x 1.5 H 2 O,其具有有价值的药理学性质,特别是对由酪氨酸激酶介导的信号转导的抑制作用,该化合物的立体选择性制备方法,特别是用于吸入合适的药物制剂及其用于治疗 疾病,特别是肿瘤疾病,良性前列腺增生和肺和气道疾病。
摘要:
The invention relates to a method for the stereoselective preparation of a compound of formula (5), optionally in the form of the tautomers thereof,
摘要:
The present invention relates to a method of preparing compounds of general formula I wherein m, n, R1 and R2 are defined as mentioned hereinafter, the enantiomers, the diastereomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases.